Overview
Toru Bando practices in Tokyo, Japan. Mr. Bando is rated as an Experienced expert by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Mediastinal Tumor, Lung Cancer, Thymic Epithelial Tumor, Lung Transplant, and Endoscopy.
His clinical research consists of co-authoring 77 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Bronchiolitis Obliterans.
Locations
Tokyo, Japan
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Lung TransplantMr. Bando isDistinguished. Learn about Lung Transplant.
- Advanced
- Lung CancerMr. Bando isAdvanced. Learn about Lung Cancer.
- Mediastinal TumorMr. Bando isAdvanced. Learn about Mediastinal Tumor.
- Experienced
- Acute Interstitial PneumoniaMr. Bando isExperienced. Learn about Acute Interstitial Pneumonia.
- Bronchiolitis ObliteransMr. Bando isExperienced. Learn about Bronchiolitis Obliterans.
- EndoscopyMr. Bando isExperienced. Learn about Endoscopy.
- Interstitial Lung DiseaseMr. Bando isExperienced. Learn about Interstitial Lung Disease.
- Lung AdenocarcinomaMr. Bando isExperienced. Learn about Lung Adenocarcinoma.
- Non-Small Cell Lung Cancer (NSCLC)Mr. Bando isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).